Edward M. Basile - Aug 4, 2025 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Director
Signature
By: /s/ Gerardo Hernandez, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Aug 4, 2025
Transactions value $
-$517,088
Form type
4
Date filed
8/5/2025, 04:30 PM
Previous filing
May 29, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Basile Edward M Director C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER By: /s/ Gerardo Hernandez, Attorney-in-Fact 2025-08-05 0001773661

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $2.9K +4.14K +144.56% $0.70 7.01K Aug 4, 2025 Direct
transaction TMDX Common Stock Sale -$520K -4.14K -59.11% $125.51 2.87K Aug 4, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise -4.14K -50.01% 4.14K Aug 4, 2025 Common Stock 4.14K $0.70 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option is fully vested.
F2 The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.